Stocks · News reference

Evommune Announces First Patient Dosed In Phase 2b Trial Of EVO756 For Migraine Prevention, Enrolling Approximately 330 Patients; Top-Line Data Expected In 2027

Jul 30, 2026, 12:07 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 26, 2026, 1:15 PMAvi Kapoor
This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Consider ACMR stock: analysts' thoughts
Read original at benzinga
ACMR EVMN FROG HRMY MT
BenzingaAug 26, 2026, 10:47 AMBenzinga Newsdesk
Needham Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $28
Needham analyst Serge Belanger initiates coverage on Evommune (NYSE:EVMN) with a Buy rating and announces Price Target of $28.
Read original at benzinga
EVMN
BenzingaAug 7, 2026, 7:21 PMBenzinga Newsdesk
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $29
RBC Capital analyst Brian Abrahams maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $30 to $29.
Read original at benzinga
EVMN
BenzingaAug 3, 2026, 10:16 AMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Neutral on Evommune
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Evommune (NYSE:EVMN) with a Neutral.
Read original at benzinga
EVMN